Epigenetics 2017 a meeting by the Australian Epigenetics Alliance

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: closed (30 April 2018) | Viewed by 374

Special Issue Editor


E-Mail Website
Guest Editor
Epigenetics and Disease Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
Interests: molecular epigenetics; chromatin dynamics; regulation of gene expression; transcriptomics; hypoxic signalling; cancer metastasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Australian Epigenetics Alliance (AEpiA) is a professional association for people engaged in Epigenetic research throughout Australia. The aim of the Australian Epigenetics Alliance is to unite and facilitate communication among all Australian research groups interested in Epigenetics-based questions. AEpiA is organising Epigenetics 2017 conference and the convening committee is hard at work to ensure the program is comprehensive, providing something for all researchers from all areas of the life science—from basic plant and model organism research, through livestock and agriculture research, to human disease diagnosis, prognosis and therapy.

This Special Issue is cooperating with the Epigenetics 2017 conference organised by AEpiA (http://epigenetics-2017.w.yrd.currinda.com/#). All speakers and registered participants at this conference are invited to submit a manuscript for publication.

Dr. Jason S. Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Epigenetic Therapies and Biomarkers 
  • Development and Inheritance
  • Epigenetic Mechanisms
  • Functionsal Epigenomics
  • Epigenetics and Disease
  • Epitranscriptome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop